Belinus Bt.

Running trials

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Active, not recruiting

  Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

  NCT04755283· Phase 2· Source

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

  NCT07357766· Phase 3· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity

  NCT06717425· Phase 2· Source

• Completed

  A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo

  NCT06131372· Phase 2· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

  NCT06323174· Phase 3· Source

• Withdrawn

  Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

  NCT06083675· Phase 3· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Source

• Completed

  A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

  NCT05646706· Phase 3· Source

• Completed

  A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

  NCT05649137· Phase 3· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Source